Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

431
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
431
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

362
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
362
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

380
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
380
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

560
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
560
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

569
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
569

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotyping of Obstructive Sleep Apnea Syndrome and Association with Cognitive Impairment, a Real-Life Study.

Biomedicines·2026
Same author

Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.

Biomedicines·2026
Same author

Innovative diagnostic techniques and their clinical implications in food allergy: current clinical practice and future perspectives.

Frontiers in allergy·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same author

Benign Bronchial Tumours: A Rare Case of Endobronchial Fibroma With Hilar-Mediastinal Lymphadenopathy.

Case reports in pulmonology·2026

Related Experiment Video

Updated: Sep 5, 2025

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety
04:20

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety

Published on: November 11, 2022

4.5K

Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic.

Vincenzo Patella1, Corrado Pelaia2, Roberta Zunno3

  • 1Department of Internal Medicine ASL Salerno, "Santa Maria della Speranza" Hospital, Salerno, Italy; Postgraduate Program in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.

Respiratory Medicine
|July 9, 2022
PubMed
Summary
This summary is machine-generated.

Biological treatments significantly improved psychological distress, anxiety, and depression in severe asthma patients during the COVID-19 pandemic. This 16-week study shows positive outcomes for asthma control and mental well-being.

Keywords:
Monoclonal antibodiesPsychological disordersSARS-CoV-2 pandemicSevere asthmaStress

More Related Videos

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.7K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Related Experiment Videos

Last Updated: Sep 5, 2025

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety
04:20

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety

Published on: November 11, 2022

4.5K
An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.7K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Area of Science:

  • Pulmonology
  • Psychiatry
  • Clinical Medicine

Background:

  • Severe asthma patients experience higher rates of psychiatric comorbidity compared to the general population.
  • Psychiatric disorders like anxiety, depression, and suicidal risk negatively impact the quality of life for asthma patients.
  • Previous research indicates a high prevalence of mental disorders among asthmatics.

Purpose of the Study:

  • To assess the real-world prevalence of psychological comorbidities in severe asthma patients treated with biologicals (Benralizumab, Mepolizumab, Omalizumab).
  • To test the hypothesis that biological treatments reduce psychological distress, anxiety, depression, and suicidal risk in severe asthma.
  • To evaluate the impact of biological therapy on asthma control and mental health during the COVID-19 pandemic.

Main Methods:

  • A cohort of 90 severe asthma patients (32 males, 58 females, mean age 53.92 ± 15.92) treated with Benralizumab, Mepolizumab, or Omalizumab were studied.
  • Clinical disease control was assessed using the Asthma Control Test (ACT) at baseline (T0) and 16 weeks (T1).
  • Psychological disorders were evaluated using the Perceived Stress Scale (PSS), Hospital Anxiety and Depression Scale (HADS-A, HADS-D), and Columbia-Suicide Severity Rating Scale (C-SSRS) at T0 and T1.

Main Results:

  • A significant improvement was observed in all measured parameters, including asthma control (ACT), perceived stress (PSS), anxiety (HADS-A), and depressive symptoms (HADS-D).
  • These improvements occurred despite the challenges posed by the COVID-19 pandemic.
  • The positive effects on disease management, stress, anxiety, and depression were consistent across different types of biological drugs used.

Conclusions:

  • Biological therapies demonstrate significant efficacy in improving psychological well-being and asthma control in patients with severe asthma.
  • The positive impact of biologicals on mental health outcomes is evident even amidst a global health crisis like the COVID-19 pandemic.
  • Treatment with biologicals offers a valuable therapeutic option for managing the complex interplay between severe asthma and psychological comorbidities.